Multiple Myeloma Clinical Trials in Boston

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Recruiting
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Beverly Hills, California
  • +85 more
2021-10-14
Oct 14, 2021
J
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Dara SC
  • Dara IV
  • Boston, Massachusetts
  • +146 more
2021-10-14
Oct 14, 2021
J
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +79 more
2021-10-14
Oct 14, 2021
N
BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • PHE885
  • Chicago, Illinois
  • +3 more
2021-10-14
Oct 14, 2021
J
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +123 more
2021-10-14
Oct 14, 2021
J
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Active, not recruiting
  • Multiple Myeloma
  • Whittier, California
  • +113 more
2021-10-14
Oct 14, 2021
J
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Daratumumab IV
  • +3 more
  • Birmingham, Alabama
  • +211 more
2021-10-14
Oct 14, 2021
A
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Scottsdale, Arizona
  • +200 more
2021-10-11
Oct 11, 2021
S
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Recruiting
  • Multiple Myeloma
  • Anchorage, Alaska
  • +533 more
2021-10-08
Oct 8, 2021
A
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies - 2019
Terminated
  • Multiple Myeloma
  • +6 more
  • AMG 397
  • +2 more
  • Birmingham, Alabama
  • +20 more
2021-10-08
Oct 8, 2021
C
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product - 2021
Terminated
  • B Cell Lymphomas
  • +3 more
  • ACTR T Cell Product
  • Gilbert, Arizona
  • +15 more
2021-10-04
Oct 4, 2021
J
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Birmingham, Alabama
  • +35 more
2021-10-07
Oct 7, 2021
J
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • JNJ-68284528
  • Phoenix, Arizona
  • +20 more
2021-10-07
Oct 7, 2021
J
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +41 more
2021-10-07
Oct 7, 2021
J
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
2021-10-07
Oct 7, 2021
J
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +56 more
2021-10-07
Oct 7, 2021
A
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • AMG 224
  • West Hollywood, California
  • +4 more
2021-09-09
Sep 9, 2021
P
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Active, not recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +45 more
2021-10-06
Oct 6, 2021
C
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +25 more
2021-10-05
Oct 5, 2021
J
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +145 more
2021-09-16
Sep 16, 2021
A
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab (TJ011133) With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Lemzoparlimab
  • +4 more
  • Tucson, Arizona
  • +48 more
2021-10-04
Oct 4, 2021
A
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Eftozanermin alfa
  • +2 more
  • Atlanta, Georgia
  • +18 more
2021-10-04
Oct 4, 2021
G
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Belantamab mafodotin frozen liquid
  • Belantamab mafodotin lyophilized powder
  • New Haven, Connecticut
  • +58 more
2021-09-30
Sep 30, 2021
O
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
Active, not recruiting
  • Multiple Myeloma
  • Tucson, Arizona
  • +108 more
2021-09-27
Sep 27, 2021
G
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +17 more
2021-09-23
Sep 23, 2021